Advertisement

Intravenous Thrombolysis

  • Lee H. Schwamm
Chapter
  • 1.5k Downloads

Keywords

Acute Stroke Acute Ischemic Stroke Thrombolytic Therapy Tissue Plasminogen Activator Intravenous Thrombolysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Collen D (1987) Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 33(2):77–86CrossRefPubMedGoogle Scholar
  2. 2.
    Collen D, Lijnen HR (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78(12):3114–3124PubMedGoogle Scholar
  3. 3.
    Freiman D (1987) The structure of thrombi. In: Colman RW, Hirsch J, Marder V et al (eds) Hemostasis and thrombosis. Lippincott, Philadelphia, Pa., pp 1123–1135Google Scholar
  4. 4.
    Ruggeri ZM (1997) Mechanisms initiating platelet thrombus formation. Thromb Haemost 78(1):611–616PubMedGoogle Scholar
  5. 5.
    Marder VJ, Sherry S (1988) Thrombolytic therapy: current status (1). N Engl J Med 318(23):1512–1520PubMedGoogle Scholar
  6. 6.
    Marder VJ, Sherry S (1988) Thrombolytic therapy: current status (2). N Engl J Med 318(24):1585–1595PubMedGoogle Scholar
  7. 7.
    Theron J et al (1989) Local intraarterial fibrinolysis in the carotid territory. Am J Neuroradiol 10(4):753–765PubMedGoogle Scholar
  8. 8.
    Pessin MS, del Zoppo GJ, Estol CJ (1990) Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 13(4):271–289PubMedGoogle Scholar
  9. 9.
    Del Zoppo GJ et al (1998) PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in acute cerebral thromboembolism. Stroke 29(1):4–11PubMedGoogle Scholar
  10. 10.
    Furlan A et al (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. J Am Med Assoc 282(21):2003–2011CrossRefGoogle Scholar
  11. 11.
    Hoylaerts M et al (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257(6):2912–2919Google Scholar
  12. 12.
    Hawkey C (1966) Plasminogen activator in saliva of the vampire bat Desmodus rotundus. Nature 211(47):434–435PubMedGoogle Scholar
  13. 13.
    Kratzschmar J et al (1991) The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 105(2):229–237CrossRefPubMedGoogle Scholar
  14. 14.
    Schleuning WD (2001) Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis 31(3–6):118–122PubMedGoogle Scholar
  15. 15.
    Bringmann P et al (1995) Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 270(43):25596–25603PubMedGoogle Scholar
  16. 16.
    Mellott MJ et al (1992) Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 12(2):212–221PubMedGoogle Scholar
  17. 17.
    Toschi L et al (1998) Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators. Eur J Biochem 252(1):108–112CrossRefPubMedGoogle Scholar
  18. 18.
    Liberatore GT et al (2003) Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 34(2): 537–543CrossRefPubMedGoogle Scholar
  19. 19.
    Hanaway J et al (1976) Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke 7(2):143–146PubMedGoogle Scholar
  20. 20.
    Fujishima M et al (1986) Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction. Angiology 37(7):487–498PubMedGoogle Scholar
  21. 21.
    Sato Y et al (1986) Anticoagulant and thrombolytic therapy for cerebral embolism of cardiac origin. Kurume Med J 33(2):89–95PubMedGoogle Scholar
  22. 22.
    Nenci GG et al (1983) Thrombolytic therapy for thromboembolism of vertebrobasilar artery. Angiology 34(9): 561–571PubMedGoogle Scholar
  23. 23.
    Del Zoppo GJ et al (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32(1):78–86PubMedGoogle Scholar
  24. 24.
    Von Kummer R, Hacke W (1992) Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 23(5):646–652Google Scholar
  25. 25.
    Yasaka M et al (1998) Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group. Neurology 50(3):626–632PubMedGoogle Scholar
  26. 26.
    The Multicenter Acute Stroke Trial Europe Study Group (1996) Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335(3):145–150Google Scholar
  27. 27.
    Multicentre Acute Stroke Trial Italy (MAST-I) Group (1995) Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346(8989):1509–1514Google Scholar
  28. 28.
    Hacke W et al (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J Am Med Assoc 274(13):1017–1025CrossRefGoogle Scholar
  29. 29.
    NINDS Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587Google Scholar
  30. 30.
    Hacke W et al (1998) Randomised double-blind placebocontrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352(9136):1245–1251CrossRefPubMedGoogle Scholar
  31. 31.
    Clark WM et al (1999) Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. J Am Med Assoc 282(21):2019–2026CrossRefGoogle Scholar
  32. 32.
    Adams HP Jr et al (1996) Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 94(5):1167–1174PubMedGoogle Scholar
  33. 33.
    Adams HP Jr et al (2003) Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 34(4):1056–1083CrossRefPubMedGoogle Scholar
  34. 34.
    Report of the Quality Standards Subcommittee of the American Academy of Neurology (1996) Practice advisory: thrombolytic therapy for acute ischemic stroke — summary statement. Neurology 47(3):835–839Google Scholar
  35. 35.
    Hacke W et al (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411):768–774PubMedGoogle Scholar
  36. 36.
    Wardlaw JM (2001) Overview of Cochrane thrombolysis meta-analysis. Neurology 57[5 Suppl 2]:S69–S76PubMedGoogle Scholar
  37. 37.
    Albers GW et al (2000) Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. J Am Med Assoc 283(9):1145–1150CrossRefGoogle Scholar
  38. 38.
    Hill MD, Buchan AM (2001) Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Can J Neurol Sci 28(3):232–238PubMedGoogle Scholar
  39. 39.
    Grond M et al (1998) Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 29(8):1544–1549PubMedGoogle Scholar
  40. 40.
    Chiu D et al (1998) Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 29(1):18–22PubMedGoogle Scholar
  41. 41.
    Trouillas P et al (1998) Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke 29(12):2529–2540PubMedGoogle Scholar
  42. 42.
    Tanne D et al (1999) Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 53(2):424–427PubMedGoogle Scholar
  43. 43.
    Akins PT et al (2000) Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke? Neurology 55(12):1801–1805PubMedGoogle Scholar
  44. 44.
    Katzan IL et al (2000) Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. J Am Med Assoc 283(9):1151–1158CrossRefGoogle Scholar
  45. 45.
    Wang DZ et al (2000) Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 31(1):77–81PubMedGoogle Scholar
  46. 46.
    Lopez-Yunez AM et al (2001) Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 32(1): 12–16PubMedGoogle Scholar
  47. 47.
    Bravata DM et al (2002) Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 162(17):1994–2001CrossRefPubMedGoogle Scholar
  48. 48.
    Merino JG et al (2002) Extending tissue plasminogen activator use to community and rural stroke patients. Stroke 33(1):141–146CrossRefPubMedGoogle Scholar
  49. 49.
    Tanne D et al (2002) Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 105(14):1679–1685CrossRefPubMedGoogle Scholar
  50. 50.
    Hacke W et al (2005) The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36(1):66–73PubMedGoogle Scholar
  51. 51.
    Albers GW et al (2004) Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126[Suppl 3]:483S–512SPubMedGoogle Scholar
  52. 52.
    Benchenane K et al (2004) Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 27(3):155–160CrossRefPubMedGoogle Scholar
  53. 53.
    Tsirka SE, Rogove AD, Strickland S (1996) Neuronal cell death and tPA. Nature 384(6605):123–124CrossRefPubMedGoogle Scholar
  54. 54.
    Wang YF et al (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4(2):228–231PubMedGoogle Scholar
  55. 55.
    Nagai N et al (1999) Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 99(18): 2440–2444PubMedGoogle Scholar
  56. 56.
    Nicole O et al (2001) The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7(1):59–64PubMedGoogle Scholar
  57. 57.
    Wang X et al (2004) Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35[11 Suppl 1]:2726–2730PubMedGoogle Scholar
  58. 58.
    Lo EH, Broderick JP, Moskowitz MA (2004) tPA and proteolysis in the neurovascular unit. Stroke 35(2):354–356CrossRefPubMedGoogle Scholar
  59. 59.
    Pfefferkorn T, Rosenberg GA (2003) Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34(8):2025–2030CrossRefPubMedGoogle Scholar
  60. 60.
    Liu D et al (2004) Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 10(12):1379–1383CrossRefPubMedGoogle Scholar
  61. 61.
    Collin C, Wade DT, Davies S, Horne V (1988) The Barthel ADL Index: a reliability study. Int Disability Study 10:61–63Google Scholar
  62. 62.
    Gresham GE, Phillips TF, Labi ML (1980) ADL status in stroke: relative merits of three standard indexes. Arch Phys Med Rehabil 61:355–358PubMedGoogle Scholar
  63. 63.
    Loewen SC, Anderson BA (1990) Predictors of stroke outcome using objective measurement scales. Stroke 21:78–81PubMedGoogle Scholar
  64. 64.
    Mahoney FI, Barthel D (1965) Functional evaluation: the Barthel Index. Maryland State Med J 14:56–61Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Lee H. Schwamm
    • 1
  1. 1.Acute Stroke ServiceMassachusetts General Hospital Harvard Medical SchoolBostonUSA

Personalised recommendations